Research programme: dendrimer-based cancer therapeutics - AstraZeneca

Drug Profile

Research programme: dendrimer-based cancer therapeutics - AstraZeneca

Alternative Names: Antibody-targeted DEP® conjugate; DEP® products - AstraZeneca; Targeted DEP™ conjugates

Latest Information Update: 25 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Dendrimers; Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Nov 2015 Preclinical trials in Cancer in Sweden (unspecified route) prior to November 2015
  • 16 Nov 2015 Pharmacodynamics data from a preclinical trial in Cancer released by Starpharma
  • 23 Sep 2015 Early research is ongoing in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top